Refining therapy for AL amyloidosis

Blood

Volumn 108, Issue 12, 2006, Pages 3632-3633

  Merlini, Giampaolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

AMYLOIDOSIS; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MORTALITY; NOTE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

EID: 33845268262     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-09-046565     Document Type: Note

References (7)

1. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
2. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004;34:1025-1031.
3. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103:2936-2938.
4. Jaccard A, Moreau P, Leblond V, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the French multicentric randomized trial (MAG and IFM Intergroup) [abstract]. Blood. 2005;106:127a. Abstract 421.
5. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. Prepublished on September 21, 2006, as DOI 10.1182/blood-2006-07-035352.
6. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase II trial. Blood. Prepublished on September 7, 2006, as DOI 10.1182/blood-2006-07-030544.
7. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. Prepublished on September 28, 2006, as DOI 10.1182/blood-2006-07-032987.